Previous Close | 2.3700 |
Open | 2.4300 |
Bid | 2.4000 x 100 |
Ask | 2.5300 x 100 |
Day's Range | 2.3900 - 2.4900 |
52 Week Range | 2.1500 - 4.8000 |
Volume | |
Avg. Volume | 34,619 |
Market Cap | 173.48M |
Beta (5Y Monthly) | 0.71 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4200 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.25 |
JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present at the following investor conferences in May 2024. Event:Guggenheim Securities Radiopharmaceuticals DayFormat:PresentationDate:May 13, 2024Time:11:30AM ETLocation:New York, NY Event:H.C. Wainwright 2ndAnnual BioConnect Investor ConferenceFormat:Fireside
JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview and update at the Jefferies Radiopharma Innovation Summit on April 11th, 2024. Event:Jefferies Radiopharma Innovation SummitDate:April 11, 2024Time:12:40-1:10 PM ESTLocation:New York, NY Mr. Levy will also be available for 1x1 inv
- Positive interim safety and feasibility data from pancreatic cancer study in Montreal, with initial signs of potential dose response findings - - ReSTART U.S. multi-center pivotal trial currently underway - - Submitted PMDA application for recurrent Head and Neck cancer in Japan - - Entered into long-term lease for a second facility in the U.S. in Hudson, NH - - Cash, deposits and restricted deposits balance of $84.9 million, with anticipated runway for at least two years - JERUSALEM, March 07